Shopping Cart 0
Cart Subtotal
AED 0

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 12845

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 25690

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 38535
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)-Pipeline Review, H2 2018

Summary

According to the recently published report 'Tyrosine Protein Kinase JAK1-Pipeline Review, H2 2018'; Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 33 molecules.

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)-JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. JAK1 plays a critical role in initiating responses to multiple major cytokine receptor families. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to escape their tumor and metastasize to other parts of the body.

The report 'Tyrosine Protein Kinase JAK1-Pipeline Review, H2 2018' outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 2, 6, 11, 12 and 2 respectively. Report covers products from therapy areas Immunology, Dermatology, Oncology, Gastrointestinal, Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Respiratory, Hematological Disorders and Ophthalmology which include indications Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Alopecia, Ulcerative Colitis, Crohn's Disease (Regional Enteritis), Vitiligo, Psoriasis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Diffuse Large B-Cell Lymphoma, Psoriatic Arthritis, Ankylosing Spondylitis (Bekhterev's Disease), B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Peripheral T-Cell Lymphomas (PTCL), Relapsed Multiple Myeloma, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Androgenic Alopecia, Arthritis, Auto Inflammatory Disease, B-Cell Chronic Lymphocytic Leukemia, Breast Cancer, Bronchiolitis Obliterans, Cancer Anorexia-Cachexia Syndrome, Chronic Asthma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Colorectal Cancer, Cutaneous Lupus Erythematosus, Cutaneous T-Cell Lymphoma, Dermatomyositis, Endometrial Cancer, Essential Thrombocythemia, Follicular Lymphoma, Gastric Cancer, Hairy Cell Leukemia, Hidradenitis Suppurativa, Hypopharyngeal Cancer, Inflammation, Inflammatory Bowel Disease, Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Leiomyosarcoma, Lupus Erythematosus, Lupus Nephritis, Marginal Zone B-cell Lymphoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Prostate Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Myelofibrosis, Myxoid Liposarcoma, Non-Hodgkin Lymphoma, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Plaque Psoriasis (Psoriasis Vulgaris), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Sicca Syndrome (Sjogren), Skin Cancer, Spondyloarthritis (Spondyloarthropathy), Synovial Sarcoma, Systemic Lupus Erythematosus, Thalassemia, Thrombocythemia Myelofibrosis, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Uveitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)

- The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

- The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)-Overview

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)-Companies Involved in Therapeutics Development

AbbVie Inc

Aclaris Therapeutics Inc

Astellas Pharma Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

CJ HealthCare Corp

Concert Pharmaceuticals Inc

Eli Lilly and Co

Galapagos NV

Han Wha Pharma Co Ltd

Incyte Corp

Japan Tobacco Inc

Jiangsu Hengrui Medicine Co Ltd

LEO Pharma A/S

Nissan Chemical Industries Ltd

Pfizer Inc

Portola Pharmaceuticals Inc

Sareum Holdings Plc

Theravance Biopharma Inc

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)-Drug Profiles

ABBV-599-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

abrocitinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-1777-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-501-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-502-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-0449-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-1480-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-4205-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

baricitinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cerdulatinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CJ-15314-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTP-543-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

delgocitinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgotinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCB-52793-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCB-54707-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

itacitinib adipate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LP-0184-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NIP-565-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peficitinib hydrobromide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06700841-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ruxolitinib phosphate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-20347-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SART-29-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SDC-1801-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SDC-1802-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-0302-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit JAK1 for Rheumatoid Arthritis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK1 and JAK3 for Inflammation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Jak1 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-1473-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

upadacitinib tartrate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YJC-50018-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)-Dormant Products

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)-Discontinued Products

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)-Product Development Milestones

Featured News & Press Releases

Nov 01, 2018: Incyte presents Itacitinib at the 60th Annual ASH meeting

Nov 01, 2018: Incyte provides data on ruxolitinib (Jakafi) at the 60th Annual ASH meeting

Nov 01, 2018: With availability of Olumiant (baricitinib), Lilly brings new oral treatment option for Canadians living with rheumatoid arthritis

Nov 01, 2018: Portola Pharmaceuticals to present new interim phase 2 results for Cerdulatinib during an oral session at the 60th American Society of Hematology (ASH) Annual Meeting

Oct 25, 2018: FDA grants priority review for Ruxolitinib (Jakafi) as a treatment for patients with acute graft-versus-host disease

Oct 23, 2018: AbbVie's Upadacitinib shows significant improvements in physical function, Pain and quality of life as a monotherapy in patients with Rheumatoid Arthritis in phase 3 patient-reported outcomes data

Oct 22, 2018: Positive trial results with Filgotinib in psoriatic arthritis and ankylosing spondylitis both published in The Lancet

Oct 22, 2018: Reistone Biopharma, a new Chinese biotech company ready to initiate its Ulcerative Colitis phase II clinical trial globally

Oct 22, 2018: Theravance Biopharma reports data from TD-1473 phase 1b four-week study in oral late-breaker presentation at UEG Week 2018

Oct 22, 2018: Positive phase 2b data for AbbVie's Upadacitinib show significant induction of clinical remission and response in patients with Ulcerative Colitis

Oct 20, 2018: Phase 3 data on Filgotinib in biologic-experienced Rheumatoid Arthritis to be presented at 2018 ACR/ARHP Annual Meeting

Oct 16, 2018: AbbVie to present data on Upadacitinib at UEG Week 2018

Oct 15, 2018: New data showcasing Lilly's growing commitment in Rheumatology to be featured at the ACR/ARHP Annual Meeting

Oct 10, 2018: Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 Selected for Oral Late-Breaker Presentation at UEG Week 2018

Oct 08, 2018: AbbVie to provides update on Upadacitinib at the 2018 ACR/ARHP Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..3), H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..4), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Products under Development by Companies, H2 2018 (Contd..5), H2 2018

Products under Development by Companies, H2 2018 (Contd..6), H2 2018

Products under Development by Companies, H2 2018 (Contd..7), H2 2018

Products under Development by Companies, H2 2018 (Contd..8), H2 2018

Products under Development by Companies, H2 2018 (Contd..9), H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by AbbVie Inc, H2 2018

Pipeline by Aclaris Therapeutics Inc, H2 2018

Pipeline by Astellas Pharma Inc, H2 2018

Pipeline by AstraZeneca Plc, H2 2018

Pipeline by Bristol-Myers Squibb Co, H2 2018

Pipeline by CJ HealthCare Corp, H2 2018

Pipeline by Concert Pharmaceuticals Inc, H2 2018

Pipeline by Eli Lilly and Co, H2 2018

Pipeline by Galapagos NV, H2 2018

Pipeline by Han Wha Pharma Co Ltd, H2 2018

Pipeline by Incyte Corp, H2 2018

Pipeline by Japan Tobacco Inc, H2 2018

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018

Pipeline by LEO Pharma A/S, H2 2018

Pipeline by Nissan Chemical Industries Ltd, H2 2018

Pipeline by Pfizer Inc, H2 2018

Pipeline by Portola Pharmaceuticals Inc, H2 2018

Pipeline by Sareum Holdings Plc, H2 2018

Pipeline by Theravance Biopharma Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Discontinued Products, H2 2018

Discontinued Products, H2 2018 (Contd..1), H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Therapeutic Products under Development, Key Players in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Therapeutics, Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Pipeline Overview, Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Pipeline, Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Pipeline Assessment


Companies

AbbVie Inc

Aclaris Therapeutics Inc

Astellas Pharma Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

CJ HealthCare Corp

Concert Pharmaceuticals Inc

Eli Lilly and Co

Galapagos NV

Han Wha Pharma Co Ltd

Incyte Corp

Japan Tobacco Inc

Jiangsu Hengrui Medicine Co Ltd

LEO Pharma A/S

Nissan Chemical Industries Ltd

Pfizer Inc

Portola Pharmaceuticals Inc

Sareum Holdings Plc

Theravance Biopharma Inc

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)-Pipeline Review, H2 2018

Summary

According to the recently published report 'Tyrosine Protein Kinase JAK1-Pipeline Review, H2 2018'; Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 33 molecules.

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)-JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. JAK1 plays a critical role in initiating responses to multiple major cytokine receptor families. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to escape their tumor and metastasize to other parts of the body.

The report 'Tyrosine Protein Kinase JAK1-Pipeline Review, H2 2018' outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 2, 6, 11, 12 and 2 respectively. Report covers products from therapy areas Immunology, Dermatology, Oncology, Gastrointestinal, Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Respiratory, Hematological Disorders and Ophthalmology which include indications Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Alopecia, Ulcerative Colitis, Crohn's Disease (Regional Enteritis), Vitiligo, Psoriasis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Diffuse Large B-Cell Lymphoma, Psoriatic Arthritis, Ankylosing Spondylitis (Bekhterev's Disease), B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Peripheral T-Cell Lymphomas (PTCL), Relapsed Multiple Myeloma, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Androgenic Alopecia, Arthritis, Auto Inflammatory Disease, B-Cell Chronic Lymphocytic Leukemia, Breast Cancer, Bronchiolitis Obliterans, Cancer Anorexia-Cachexia Syndrome, Chronic Asthma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Colorectal Cancer, Cutaneous Lupus Erythematosus, Cutaneous T-Cell Lymphoma, Dermatomyositis, Endometrial Cancer, Essential Thrombocythemia, Follicular Lymphoma, Gastric Cancer, Hairy Cell Leukemia, Hidradenitis Suppurativa, Hypopharyngeal Cancer, Inflammation, Inflammatory Bowel Disease, Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Leiomyosarcoma, Lupus Erythematosus, Lupus Nephritis, Marginal Zone B-cell Lymphoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Prostate Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Myelofibrosis, Myxoid Liposarcoma, Non-Hodgkin Lymphoma, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Plaque Psoriasis (Psoriasis Vulgaris), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Sicca Syndrome (Sjogren), Skin Cancer, Spondyloarthritis (Spondyloarthropathy), Synovial Sarcoma, Systemic Lupus Erythematosus, Thalassemia, Thrombocythemia Myelofibrosis, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Uveitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)

- The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

- The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)-Overview

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)-Companies Involved in Therapeutics Development

AbbVie Inc

Aclaris Therapeutics Inc

Astellas Pharma Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

CJ HealthCare Corp

Concert Pharmaceuticals Inc

Eli Lilly and Co

Galapagos NV

Han Wha Pharma Co Ltd

Incyte Corp

Japan Tobacco Inc

Jiangsu Hengrui Medicine Co Ltd

LEO Pharma A/S

Nissan Chemical Industries Ltd

Pfizer Inc

Portola Pharmaceuticals Inc

Sareum Holdings Plc

Theravance Biopharma Inc

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)-Drug Profiles

ABBV-599-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

abrocitinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-1777-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-501-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-502-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-0449-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-1480-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-4205-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

baricitinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cerdulatinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CJ-15314-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTP-543-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

delgocitinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgotinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCB-52793-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCB-54707-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

itacitinib adipate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LP-0184-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NIP-565-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peficitinib hydrobromide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06700841-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ruxolitinib phosphate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-20347-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SART-29-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SDC-1801-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SDC-1802-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-0302-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit JAK1 for Rheumatoid Arthritis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK1 and JAK3 for Inflammation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Jak1 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-1473-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

upadacitinib tartrate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YJC-50018-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)-Dormant Products

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)-Discontinued Products

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)-Product Development Milestones

Featured News & Press Releases

Nov 01, 2018: Incyte presents Itacitinib at the 60th Annual ASH meeting

Nov 01, 2018: Incyte provides data on ruxolitinib (Jakafi) at the 60th Annual ASH meeting

Nov 01, 2018: With availability of Olumiant (baricitinib), Lilly brings new oral treatment option for Canadians living with rheumatoid arthritis

Nov 01, 2018: Portola Pharmaceuticals to present new interim phase 2 results for Cerdulatinib during an oral session at the 60th American Society of Hematology (ASH) Annual Meeting

Oct 25, 2018: FDA grants priority review for Ruxolitinib (Jakafi) as a treatment for patients with acute graft-versus-host disease

Oct 23, 2018: AbbVie's Upadacitinib shows significant improvements in physical function, Pain and quality of life as a monotherapy in patients with Rheumatoid Arthritis in phase 3 patient-reported outcomes data

Oct 22, 2018: Positive trial results with Filgotinib in psoriatic arthritis and ankylosing spondylitis both published in The Lancet

Oct 22, 2018: Reistone Biopharma, a new Chinese biotech company ready to initiate its Ulcerative Colitis phase II clinical trial globally

Oct 22, 2018: Theravance Biopharma reports data from TD-1473 phase 1b four-week study in oral late-breaker presentation at UEG Week 2018

Oct 22, 2018: Positive phase 2b data for AbbVie's Upadacitinib show significant induction of clinical remission and response in patients with Ulcerative Colitis

Oct 20, 2018: Phase 3 data on Filgotinib in biologic-experienced Rheumatoid Arthritis to be presented at 2018 ACR/ARHP Annual Meeting

Oct 16, 2018: AbbVie to present data on Upadacitinib at UEG Week 2018

Oct 15, 2018: New data showcasing Lilly's growing commitment in Rheumatology to be featured at the ACR/ARHP Annual Meeting

Oct 10, 2018: Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 Selected for Oral Late-Breaker Presentation at UEG Week 2018

Oct 08, 2018: AbbVie to provides update on Upadacitinib at the 2018 ACR/ARHP Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..3), H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..4), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Products under Development by Companies, H2 2018 (Contd..5), H2 2018

Products under Development by Companies, H2 2018 (Contd..6), H2 2018

Products under Development by Companies, H2 2018 (Contd..7), H2 2018

Products under Development by Companies, H2 2018 (Contd..8), H2 2018

Products under Development by Companies, H2 2018 (Contd..9), H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by AbbVie Inc, H2 2018

Pipeline by Aclaris Therapeutics Inc, H2 2018

Pipeline by Astellas Pharma Inc, H2 2018

Pipeline by AstraZeneca Plc, H2 2018

Pipeline by Bristol-Myers Squibb Co, H2 2018

Pipeline by CJ HealthCare Corp, H2 2018

Pipeline by Concert Pharmaceuticals Inc, H2 2018

Pipeline by Eli Lilly and Co, H2 2018

Pipeline by Galapagos NV, H2 2018

Pipeline by Han Wha Pharma Co Ltd, H2 2018

Pipeline by Incyte Corp, H2 2018

Pipeline by Japan Tobacco Inc, H2 2018

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018

Pipeline by LEO Pharma A/S, H2 2018

Pipeline by Nissan Chemical Industries Ltd, H2 2018

Pipeline by Pfizer Inc, H2 2018

Pipeline by Portola Pharmaceuticals Inc, H2 2018

Pipeline by Sareum Holdings Plc, H2 2018

Pipeline by Theravance Biopharma Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Discontinued Products, H2 2018

Discontinued Products, H2 2018 (Contd..1), H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Therapeutic Products under Development, Key Players in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Therapeutics, Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Pipeline Overview, Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Pipeline, Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Pipeline Assessment


Companies

AbbVie Inc

Aclaris Therapeutics Inc

Astellas Pharma Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

CJ HealthCare Corp

Concert Pharmaceuticals Inc

Eli Lilly and Co

Galapagos NV

Han Wha Pharma Co Ltd

Incyte Corp

Japan Tobacco Inc

Jiangsu Hengrui Medicine Co Ltd

LEO Pharma A/S

Nissan Chemical Industries Ltd

Pfizer Inc

Portola Pharmaceuticals Inc

Sareum Holdings Plc

Theravance Biopharma Inc